跳至主要内容
临床试验/2025-523349-86-00
2025-523349-86-00招募中3 期

MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction

Assistance Publique Hopitaux De Paris10 个研究点 分布在 1 个国家目标入组 700 人开始时间: 2026年2月2日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
700
试验地点
10
主要终点
Proportion of patients achieving pain relief, i.e. pain intensity score on visual analogic scale (VAS) ≤ 3 at 30 minutes.

研究概览

简要总结

To demonstrate that methoxyflurane self-administered by the patient suffering chest pain related to an acute myocardial infarction is at least as efficient in achieving pain relief that morphine.

研究设计

分配方式
Randomized
主要目的
Mami
盲法
None

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • Patient age ≥ 18 years
  • Patient managed in pre-hospital setting for a ST elevation myocardial infarction (STEMI) : Chest pain < 12 hours with moderate to severe pain (VAS > 6/10).
  • Patient managed in pre-hospital setting for a ST elevation myocardial infarction (STEMI): STEMI on ECG according to 2017 ESC guidelines

排除标准

  • Previous analgesic treatment for this episode of chest pain
  • Clinical evidence of cardiovascular instability (PAS <90 mm Hg)
  • Altered level of consciousness due to any cause, including head trauma, drug or alcohol use.
  • Clinically significant renal impairment.
  • History of signs of liver damage after use of methoxyflurane or after anesthesia with a halogenated hydrocarbon.
  • Severe hepatocellular insufficiency (with encephalopathy),,
  • Acute head trauma and intracranial hypertension in the absence of controlled ventilation,
  • Uncontrolled epilepsy
  • Treatment with buprenorphine, nalbuphine and pentazocine, naltrexone, nalmefene or sodium oxybate
  • Breastfeeding, in case of initiation or continuation after birth of a long-term treatment.
  • Malignant hyperthermia: known malignant hyperthermia or genetic predisposition of the patient.
  • Hypersensitivity to morphine, methoxyflurane, any fluorinated anesthetic or any of the excipients listed in SmPC
  • History of serious adverse effects of the patient or his family after administration of inhaled anesthetics.
  • Incapacity to self-assess pain intensity
  • Incapacity to methoxyflurane self-administration
  • Pregnancy, minors or incapacity (tutelle, curatelle)
  • Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants
  • Absence of a Social Security
  • Clinical evidence of respiratory depression.
  • Decompensated respiratory failure (in the absence of artificial ventilation),

结局指标

主要结局

Proportion of patients achieving pain relief, i.e. pain intensity score on visual analogic scale (VAS) ≤ 3 at 30 minutes.

Proportion of patients achieving pain relief, i.e. pain intensity score on visual analogic scale (VAS) ≤ 3 at 30 minutes.

次要结局

  • Pain relief: time before achieving pain relief, i.e. time between randomization and pain intensity score on VAS ≤ 3;
  • Pain relief: time to reach initial pain divided by two (initial VAS / 2)
  • Impact of the treatments on cardiovascular system: heart rate, arterial blood pressure, pulse oximetry and ECG changes at hospital arrival
  • Tolerance of the treatments: respiratory depression: respiratory rate < 10 cycles per minutes
  • Tolerance of the treatments: sedation: Richmond Agitation - Sedation Scale (RASS) ≥ 2 or ≤ -2
  • Tolerance of the treatments: : dizziness, pruritus, nausea, vomiting, headache

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Frédéric LAPOSTOLLE

Scientific

Assistance Publique Hopitaux De Paris

研究点 (10)

Loading locations...

相似试验